> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Kiniksa Stock Soars 22%, Adding $1.3 Billion, After Raising Its Arcalyst Forecast
- URL: https://www.bullished.co/kiniksa-stock-soars-22-adding-1-3-billion-after-raising-its-arcalyst-forecast-2e4b7efb/
- Published: 2026-10-28T12:16:41.000Z
- Updated: 2026-10-28T12:16:41.000Z
- Description: The drugmaker's shares hit a 52-week high after third-quarter profit climbed and management lifted its full-year Arcalyst outlook.
- Author: Matteo Parrino
- Tags: Markets, KNSA, Industry: Healthcare

[Kiniksa Pharmaceuticals International](https://www.bullished.co/tag/knsa/), which sells the pericarditis drug Arcalyst, saw its shares soar 22.23% to $89.20 at Tuesday's close, a new 52-week high, after it [raised its full-year Arcalyst sales forecast](https://seekingalpha.com/news/4658045-kiniksa-stock-jumps-q3-2026-results?ref=bullished.co) alongside third-quarter results. The jump added $1.3 billion in market value.

## Forecast lifted to $1.05 billion

In an [8-K](https://www.sec.gov/Archives/edgar/data/0001730430/000173043026000037/knsa-20261027x8k.htm?ref=bullished.co) filed Tuesday, Kiniksa raised its 2026 Arcalyst net product revenue forecast to a range of $1.045 billion to $1.050 billion. The prior range was $980 million to $995 million.

Third-quarter revenue reached [$286 million](https://www.sec.gov/Archives/edgar/data/1730430/000110465926119186/knsa-20260930x10q.htm?ref=bullished.co), up 58.1% from a year earlier, the company reported. Profit was $47.3 million, up from $18.4 million a year earlier, according to a [MarketWatch report](https://www.marketwatch.com/story/kiniksa-pharma-shares-gain-on-higher-3q-profit-revenue-5cafb88f?ref=bullished.co) on the results.

It was the stock's biggest one-day gain since July 28, when it rose 25.0%. Kiniksa's total market value stood at $6.96 billion at Tuesday's close.

## A pericarditis drug carries the company

Kiniksa, a biopharmaceutical company focused on heart and blood vessel conditions, has one commercial product: Arcalyst, a weekly injection approved in the United States for recurrent pericarditis, a painful inflammation of the sac around the heart. It is also approved for two rare inflammatory conditions, CAPS and DIRA. Kiniksa licenses the drug from Regeneron, which makes it and splits profits with Kiniksa evenly.

The stock entered the session [up about 77%](https://www.marketwatch.com/story/kiniksa-pharma-shares-gain-on-higher-3q-profit-revenue-5cafb88f?ref=bullished.co) this year as of Monday's close, well ahead of the [S&P 500's gain of about 12%](https://finance.yahoo.com/healthcare/articles/kiniksa-pharmaceuticals-international-plc-knsa-115002734.html?.tsrc=rss&ref=bullished.co).

## Blockbuster talk and a 2027 readout

Management said on the day of the results that Arcalyst is positioned to reach blockbuster status this year. A late-stage readout for the monthly follow-on drug is due in the second half of 2027, ahead of a possible launch in 2028 to 2029.

The next hard data point is the second half of 2027, when the late-stage readout on Kiniksa's monthly follow-on drug is due.

### Sources

- [Kiniksa stock jumps after Q3 2026 results (KNSA:NASDAQ)](https://seekingalpha.com/news/4658045-kiniksa-stock-jumps-q3-2026-results?ref=bullished.co) — seekingalpha.com
- [Kiniksa Pharma Shares Gain on Higher 3Q Profit, Revenue](https://www.marketwatch.com/story/kiniksa-pharma-shares-gain-on-higher-3q-profit-revenue-5cafb88f?ref=bullished.co) — MarketWatch
- [Kiniksa Pharmaceuticals International, plc GAAP EPS of $0.56 beats by $0.21, revenue of $286M | Seeking Alpha](https://seekingalpha.com/news/4657791-kiniksa-pharmaceuticals-international-plc-gaap-eps-of-0%5F56-beats-by-0%5F21-revenue-of-286m?ref=bullished.co) — seekingalpha.com
- [12 Health Care Stocks Moving In Tuesday's Intraday Session](https://www.benzinga.com/trading-ideas/movers/26/10/62629384/12-health-care-stocks-moving-tuesday-s-intraday-session?ref=bullished.co) — benzinga.com
- [Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates](https://finance.yahoo.com/healthcare/articles/kiniksa-pharmaceuticals-international-plc-knsa-115002734.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Kiniksa Lifts Arcalyst Forecast To Up To $1.050 Billion As Third-Quarter Profit Climbs](https://www.sec.gov/Archives/edgar/data/0001730430/000173043026000037/knsa-20261027x8k.htm?ref=bullished.co) — SEC filing
- [Kiniksa Pharmaceuticals International — Form 10-Q for the quarter ended 2026-09-30 (quarterly results)](https://www.sec.gov/Archives/edgar/data/1730430/000110465926119186/knsa-20260930x10q.htm?ref=bullished.co) — SEC EDGAR

### More on Kiniksa Pharmaceuticals International

- [Kiniksa's Semi-Finished Drug Stock Hits $76.2 Million As Samsung Takes Over Manufacturing](https://www.bullished.co/kiniksas-semi-finished-drug-stock-hits-76-2-million-as-samsung-takes-over-manufacturing-d19f65a9/)
- [Kiniksa CEO On Deals With Cash Piling Up: 'The Bar Is Exceedingly High'](https://www.bullished.co/kiniksa-ceo-on-deals-with-cash-piling-up-the-bar-is-exceedingly-high-14512498/)
- [Kiniksa Sets Second-Half 2027 Data Date For Monthly Heart Drug, Eyes 2028-2029 Launch](https://www.bullished.co/kiniksa-sets-second-half-2027-data-date-for-monthly-heart-drug-eyes-2028-2029-launch-bd3bfaf1/)

[All Kiniksa Pharmaceuticals International (KNSA) coverage →](https://www.bullished.co/tag/knsa/)